Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1 | Zendy

Benjamin P. Linas | Zendy; Jake R. Morgan | Zendy; Mai T. Pho | Zendy; Jared A. Leff | Zendy; Bruce R. Schackman | Zendy; C. Robert Horsburgh | Zendy; Sabrina A. Assoumou | Zendy; Joshua A. Salomon | Zendy; Milton C. Weinstein | Zendy; Kenneth A. Freedberg | Zendy; Arthur Y. Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

Author(s) -

Benjamin P. Linas,

Jake R. Morgan,

Mai T. Pho,

Jared A. Leff,

Bruce R. Schackman,

C. Robert Horsburgh,

Sabrina A. Assoumou,

Joshua A. Salomon,

Milton C. Weinstein,

Kenneth A. Freedberg,

Arthur Y. Kim

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw266

Subject(s) - medicine , regimen , cost effectiveness , hepatitis c , intensive care medicine , risk analysis (engineering)

Treatment strategies using interferon-free therapies to treat all HCV-infected persons are cost effective, but short-term cost is high. Among noncirrhotic patients, using the least costly interferon-free regimen, even if it is not single tablet or once daily, is the cost-control strategy that results in best outcomes. Restricting treatment to patients with more advanced disease often results in worse outcomes than treating all patients, and it is not preferred.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research